Bacillus Calmette-Guérin (BCG) shortages and the fragile BCG supply chain have created a bladder cancer treatment vacuum.

The FDA has expanded the approval of Winrevair to include treatment of adults with PAH WHO Group 1 to improve exercise capacity and WHO FC, and reduce the risk of clinical worsening events including ...

The phase 3 ALBAN trial tested atezolizumab plus BCG in BCG-naïve patients with high-risk, non-muscle-invasive bladder cancer (NMIBC).

PlGF cutoff <100 pg/mL demonstrated 100 percent sensitivity and specificity at 20 to 24 weeks of gestation for early-onset preeclampsia.

(HealthDay News) — Primary care physicians (PCPs) spend an average of 61.8 hours per week caring for a patient panel, according to a study published online Oct. 21 in the Annals of Internal Medicine.

ASN’s Kidney Week 2025 is happening November 5-9, 2025 at the George R. Brown Convention Center in Houston, Texas.

(HealthDay News) — Macrovascular infiltration and spikes in circulating tumor cell (CTC) clusters are associated with cancer mortality, according to a study published online Oct. 16 in Nature Medicine ...

The phase 3 POTOMAC trial tested durvalumab added to BCG in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).

Adding durvalumab to induction and maintenance with Bacillus Calmette–Guérin (BCG) can improve disease-free survival in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer, data ...

(HealthDay News) — More than one in five young adults report using cannabis or alcohol to get to sleep, according to a research letter published online Oct. 13 in JAMA Pediatrics.

Adding EV and pembrolizumab to surgical treatment can improve outcomes in MIBC patients who are ineligible for cisplatin, data suggest.

Smaller declines seen in early-stage cancer diagnosis during COVID-19 pandemic in adults aged 18 to 44 years, men, those with high comorbidity burden.